Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 Following Topical Single and Multiple Ascending Dose Administration

NCT05428449 is registered in ClinicalTrials.gov with Suzhou Kintor Pharmaceutical Inc, as lead sponsor.

NCT NCT05428449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05428449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 Following Topical Single and Multiple Ascending Dose Administration
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Phase
Phase 1
Overall status
Completed
Start date
February 10, 2022
Completion date
April 6, 2023
Enrollment
123 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris, androgenetic alopecia